Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice

Antimicrobial Agents and Chemotherapy
Liisa TörmäkangasPekka Saikku

Abstract

Chronic Chlamydia pneumoniae infections have been associated with atherosclerosis, but clear knowledge about how these infections should be treated is lacking. We studied the effect of a new ketolide antibiotic, telithromycin, on chronic C. pneumoniae lung infection. Female C57BL/6J mice on a 0.2% cholesterol diet were inoculated intranasally with C. pneumoniae either two or three times every fourth week. Telithromycin was given to the mice subcutaneously at 75 mg/kg of body weight once daily for 5 or 10 days, starting at 3 days after the last inoculation. Samples were taken at 4 and 12 weeks after the last inoculation. The presence of C. pneumoniae DNA in lung tissue was demonstrated by PCR and the detection of lipid accumulation in the aortic sinus by Oil-Red-O staining. C. pneumoniae DNA positivity and inflammatory reactions in the lung tissue of the mice inoculated twice were significantly affected by treatment after both inoculations or only after the second inoculation at 12 weeks. Intimal lipid accumulation in the aortic sinus was also slightly but significantly less abundant in the mice treated after both inoculations compared to the levels in those treated only after the second inoculation for 10 days (geometric means,...Continue Reading

References

Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M R HammerschlagJ Schachter
Jul 10, 1991·JAMA : the Journal of the American Medical Association·D L HahnR Golubjatnikov
Sep 1, 1989·Antimicrobial Agents and Chemotherapy·K ChirgwinM R Hammerschlag
Feb 1, 1988·Antimicrobial Agents and Chemotherapy·C C Kuo, J T Grayston
Dec 1, 1987·Atherosclerosis·B PaigenR A Williams
Aug 1, 1995·The Journal of Infectious Diseases·R MalinverniJ T Grayston
Jul 1, 1994·Antimicrobial Agents and Chemotherapy·P M RoblinM R Hammerschlag
Sep 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M R EkmanP Saikku
May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·W L BeattyR P Morrison
May 1, 1993·Infection and Immunity·Z P YangJ T Grayston
Apr 1, 1996·Infection and Immunity·K LaitinenP Saikku
Jan 1, 1996·Scandinavian Journal of Infectious Diseases·G FalckH Gnarpe
Apr 1, 1997·The Journal of Infectious Diseases·T C MoazedL A Campbell
Apr 1, 1997·Epidemiology and Infection·L Von HertzenP Saikku
May 14, 1998·The Journal of Antimicrobial Chemotherapy·M T Labro
May 14, 1998·The Journal of Antimicrobial Chemotherapy·F Scaglione, G Rossoni
May 21, 1998·The Journal of Infectious Diseases·T C MoazedL A Campbell
Jun 13, 1998·Antimicrobial Agents and Chemotherapy·P M Roblin, M R Hammerschlag
Feb 20, 1999·Infection and Immunity·S AirenneA Laurila
Feb 27, 1999·Antimicrobial Agents and Chemotherapy·K E PiperR Patel
Oct 26, 1999·Infection and Immunity·I W FongJ B Mahony
Nov 5, 1999·Clinical and Diagnostic Laboratory Immunology·I W FongJ B Mahony
May 29, 2000·The Journal of Antimicrobial Chemotherapy·M R Hammerschlag
Jun 6, 2000·The Journal of Infectious Diseases·L A CampbellC Kuo
Dec 20, 2000·The Journal of Infectious Diseases·N M RothsteinC J Lowenstein
Apr 17, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·K Aalto-SetäläP Saikku
May 17, 2001·Antimicrobial Agents and Chemotherapy·A BonnefoyA M Girard
Aug 29, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S Douthwaite
Sep 5, 2001·The Journal of Antimicrobial Chemotherapy·N MiyashitaT Matsushima
Apr 3, 2002·Circulation·Juha SinisaloUNKNOWN Clarithromycin in Acute Coronary Syndrome Patients in Finland (CLARIFY) Study Group
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Ignatius W FongJames B Mahony

❮ Previous
Next ❯

Citations

Nov 15, 2011·Journal of Agricultural and Food Chemistry·Olli SalinPia M Vuorela
Aug 21, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Antonietta RizzoMaria Rosaria Iovene
Feb 27, 2008·Journal of Cellular and Molecular Medicine·Anna OksaharjuKen A Lindstedt
Jan 18, 2006·Biochemical Pharmacology·J AlvesaloP Vuorela

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.